close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

3.050 +0.200 (+7.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 73,404
Open 2.930
Bid (Size) 2.700 (200)
Ask (Size) 3.150 (400)
Prev. Close 2.850
Today's Range 2.850 - 3.050
52wk Range 2.750 - 43.65
Shares Outstanding 1,524,535
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
-25.2%
-25.2%
1 Month
-23.4%
-23.4%
3 Month
-21.6%
-21.6%
6 Month
-92.4%
-92.4%
1 Year
-83.3%
-83.3%

More News

Read More
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
TVRD SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
From Tvardi Therapeutics, Inc.
Via Business Wire
News headline image
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Tvardi Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – TVRD
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Unusual volume stocks in Monday's session ↗
Via Chartmill
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
Unusual volume stocks in Wednesday's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks ↗
Via Benzinga

Frequently Asked Questions

Is Tvardi Therapeutics, Inc. - Common Stock publicly traded?
Yes, Tvardi Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Tvardi Therapeutics, Inc. - Common Stock trade on?
Tvardi Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tvardi Therapeutics, Inc. - Common Stock?
The ticker symbol for Tvardi Therapeutics, Inc. - Common Stock is TVRD on the Nasdaq Stock Market
What is the current price of Tvardi Therapeutics, Inc. - Common Stock?
The current price of Tvardi Therapeutics, Inc. - Common Stock is 3.050
When was Tvardi Therapeutics, Inc. - Common Stock last traded?
The last trade of Tvardi Therapeutics, Inc. - Common Stock was at 04/08/26 04:00 PM ET
What is the market capitalization of Tvardi Therapeutics, Inc. - Common Stock?
The market capitalization of Tvardi Therapeutics, Inc. - Common Stock is 4.65M
How many shares of Tvardi Therapeutics, Inc. - Common Stock are outstanding?
Tvardi Therapeutics, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today